Literature DB >> 19643480

A surgical strategy for the correction of Fraser syndrome cryptophthalmos.

George M Saleh1, Badrul Hussain, David H Verity, J Richard O Collin.   

Abstract

PURPOSE: To describe a systematic approach for managing the structural adnexal anomalies encountered in Fraser syndrome, a multisystem, autosomal recessive condition associated with cryptophthalmos.
DESIGN: Retrospective, noncomparative, interventional case series. PARTICIPANTS: All patients with Fraser syndrome-related cryptophthalmos managed at a Moorfields Eye Hospital during a 23-year period between 1984 and 2007.
METHODS: All patients' clinical records were reviewed. The age of the patient at presentation, sex, ethnic origin, parental consanguinity, associated systemic features, length of follow-up, and surgical interventions were recorded. MAIN OUTCOME MEASURES: The sequence of surgical procedures performed for the different morphologic cryptophthalmos subtypes, postoperative visual acuity, and corneal survival.
RESULTS: The study includes 13 eyes of 7 patients. Cryptophthalmos was complete in 3 eyes and abortive in 10 eyes; no cases of incomplete cryptophthalmos were encountered in this series. The aim of surgical intervention in the latter was to optimize visual potential. Surgical steps included dissection of corneal adhesions from keratinized cornea, mucous membrane graft, Mustarde eyelid switch flap with subsequent division, and further lower lid augmentation as required (n = 10). For complete cryptophthalmos, surgery was recommended if cosmetic improvement was sought and enough tissue remained after any repair of abortive cryptophthalmos in the fellow eye. Surgery in these cases involved the creation of fornices, with subsequent upper and lower lid reconstruction with local skin/muscle flaps (n = 1). Postoperative acuities ranged from perception of light to 20/200. Good outcomes in terms of corneal health were achieved in 6 of the 10 eyes operated on for incomplete cryptophthalmos.
CONCLUSIONS: Although Fraser syndrome is rare, the periocular surgical management of these complex cases may be planned using a systematic approach as described in this study, which is the largest such series to date. FINANCIAL DISCLOSURE(S): The author(s) have no proprietary or commercial interest in any materials discussed in this article.

Entities:  

Mesh:

Year:  2009        PMID: 19643480     DOI: 10.1016/j.ophtha.2009.05.018

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  6 in total

1.  Eyelid and fornix reconstruction in abortive cryptophthalmos: a single-center experience over 12 years.

Authors:  J Ding; Z Hou; Y Li; N Lu; D Li
Journal:  Eye (Lond)       Date:  2017-06-16       Impact factor: 3.775

2.  Manifestation and grading of ocular involvement in patients with Tessier number 10 clefts.

Authors:  C Shao; W Lu; J Li; J Chen; Q Yao; X Fan; Y Fu
Journal:  Eye (Lond)       Date:  2017-03-17       Impact factor: 3.775

Review 3.  Congenital upper eyelid coloboma: embryologic, nomenclatorial, nosologic, etiologic, pathogenetic, epidemiologic, clinical, and management perspectives.

Authors:  Hatem A Tawfik; Mohamed H Abdulhafez; Yousef A Fouad
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2015 Jan-Feb       Impact factor: 1.746

Review 4.  Clinical features and orbital anomalies in Fraser syndrome and a review of management options.

Authors:  Deepsekhar Das; Sujeeth Modaboyina; Sandton Raj; Sahil Agrawal; Mandeep Singh Bajaj
Journal:  Indian J Ophthalmol       Date:  2022-07       Impact factor: 2.969

5.  Prenatal diagnosis of Fraser syndrome: a matter of life or death?

Authors:  Giuseppe De Bernardo; Maurizio Giordano; Antonino Di Toro; Desiree Sordino; Daniele De Brasi
Journal:  Ital J Pediatr       Date:  2015-11-09       Impact factor: 2.638

Review 6.  Embryologic and Fetal Development of the Human Eyelid.

Authors:  Hatem A Tawfik; Mohamed H Abdulhafez; Yousef A Fouad; Jonathan J Dutton
Journal:  Ophthalmic Plast Reconstr Surg       Date:  2016 Nov/Dec       Impact factor: 1.746

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.